SCHEMBL6841550

SCHEMBL6841550

CCN(C)c1ccc(Cc2ccc(N(C)CC)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.61
TDP1 Q9NUW8 4/20 0.61
TSHR P16473 4/20 0.61
CYP3A4 P08684 3/20 0.61
MAPK1 P28482 2/20 0.61
ADRA2A P08913 2/20 0.48
ADRA2B P18089 2/20 0.48
ADRA2C P18825 2/20 0.48
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
IGLV6-57 P01721 1/20 0.40
ALDH3A1 P30838 1/20 0.37
ALDH1A3 P47895 1/20 0.37
CNR2 P34972 1/20 0.36
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
HTT P42858 2/20 0.35
CYP1A2 P05177 1/20 0.35
LTA4H P09960 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12680471 1.00 ALDH1A1 (0.61) ALDH1A1TDP1TSHRCYP3A4MAPK1
SCHEMBL12679045 0.93 ALDH1A1 (0.74) ALDH1A1TDP1TSHRCYP3A4MAPK1
SCHEMBL10330355 0.87 ADRA2A (0.58) ALDH1A1TDP1TSHRCYP3A4MAPK1
SCHEMBL12894331 0.85 ADRA2A (0.48) ALDH1A1TDP1TSHRCYP3A4MAPK1
SCHEMBL15014122 0.81 ADRA2A (0.50) ALDH1A1TDP1TSHRCYP3A4MAPK1
SCHEMBL4400993 0.79 ADRA2A (0.52) ALDH1A1TDP1TSHRCYP3A4MAPK1
SCHEMBL18323114 0.79 ADRA2A (0.52) ALDH1A1TDP1TSHRCYP3A4MAPK1
SCHEMBL762882 0.79 ALDH1A1 (0.61) ALDH1A1TDP1TSHRCYP3A4MAPK1
SCHEMBL24464098 0.78 ADRA2A (0.43) ALDH1A1TDP1TSHRCYP3A4MAPK1
SCHEMBL1655689 0.77 ALDH1A1 (0.60) ALDH1A1TDP1TSHRCYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4419431-A One- or two-component diazo-type material with diphenyl diamine as light fade inhibitor VEB FILMFABRIK WOLFEN (DD) 1983-12-06 US claimed
US-6797841-B2 HAVING PHOTOINITIATION ACTIVITY WITH MINIMAL OR NO ADVERSE HAZARDOUS CHARACTERISTICS ALBEMARLE CORPORATION 2004-09-28 US disclosed
US-6781015-B2 PHOTOPOLYMERIZATION ALBEMARLE CORPORATION 2004-08-24 US disclosed
US-6762323-B2 EXPOSING A FORMUALTION CONTAINING A PIGMENT AND A PHOTOPOLYMERIZABLE COMPOUND HAVING AN ETHYLENICALLY UNSATURATED DOUBLE BOND TO RADIATION IN PRESENCE NON-MUTAGENIC PHOTOINITIATOR ALBEMARLE CORPORATION 2004-07-13 US disclosed
US-20030078313-A1 Aminobenzophenones and photopolymerizable compositions including the same ALBEMARLE CORPORATION 2003-04-24 US disclosed
US-20030073754-A1 Aminobenzophenones and photopolymerizable compositions including the same ALBEMARLE CORPORATION 2003-04-17 US disclosed
US-20030065049-A1 Aminobenzophenones and photopolymerizable compositions including the same ALBEMARLE CORPORATION 2003-04-03 US disclosed
US-6479706-B1 Aminobenzophenones and photopolymerizable compositions including the same ALBEMARLE CORPORATION 2002-11-12 US disclosed
US-4419431-A One- or two-component diazo-type material with diphenyl diamine as light fade inhibitor VEB FILMFABRIK WOLFEN (DD) 1983-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073754-A1 Aminobenzophenones and photopolymerizable compositions including the same TYR, AASDHPPT, ALAD ALDH1A1 864/4885TDP1 2147/4885TSHR 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.